Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
26 avr. 2024 20h38 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today
09 avr. 2024 16h05 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives...
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024
01 avr. 2024 07h15 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina Therapeutics” or the “Company”), a biopharmaceutical company dedicated to...
Rakovina Therapeutics Announces Strategic Pivot to AI
27 mars 2024 16h05 HE
|
Rakovina Therapeutics Inc
Rakovina Therapeutics announces Artificial Intelligence (AI) collaboration
Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update
27 nov. 2023 19h43 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
Rakovina Therapeutics Welcomes Prof. Artem Cherkasov to the Company’s Scientific Advisory Board
27 nov. 2023 09h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage...
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
20 nov. 2023 09h13 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage...
Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update
29 août 2023 08h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
Rakovina Therapeutics Announces Results from 2023 Annual General Meeting
28 juin 2023 22h55 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update
31 mai 2023 09h05 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...